Sildigra Softgel represents a significant advancement in the oral pharmacotherapy of erectile dysfunction (ED). This formulation utilizes sildenafil citrate, a potent and selective inhibitor of phosphodiesterase type 5 (PDE5), delivered in a highly bioavailable softgel capsule. The softgel technology enhances the pharmacokinetic profile, potentially leading to a more rapid onset of action and consistent therapeutic plasma levels. It is designed for adult males experiencing vasculogenic erectile insufficiency, offering a reliable and convenient treatment option that targets the underlying physiological mechanism of erection.

Features

• Active Pharmaceutical Ingredient: Sildenafil Citrate (typically 25mg, 50mg, or 100mg strengths).
• Pharmaceutical Form: Softgel capsule for oral administration.
• Advanced Delivery System: Lipid-based encapsulation designed for improved solubility and absorption.
• Excipients: Includes gelatin, glycerin, purified water, and pharmaceutical-grade solubilizers.
• Mechanism of Action: Highly selective competitive inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).

Benefits

• Facilitates the achievement and maintenance of an erection sufficient for sexual activity when combined with sexual stimulation.
• The softgel formulation may allow for a faster onset of action compared to standard tablet forms due to enhanced bioavailability.
• Provides a predictable and reliable therapeutic response, helping to reduce anxiety associated with sexual performance.
• The convenient oral dosage form supports discretion and ease of use, integrating seamlessly into a patient’s routine.
• Effective management of erectile dysfunction can contribute to improved self-esteem and relationship satisfaction.

Common use

Sildigra Softgel is indicated for the treatment of erectile dysfunction (ED) in adult men. Its use is predicated on the presence of sexual stimulation; it does not independently cause an erection. It is suitable for patients with ED of various etiologies, including vasculogenic, neurogenic, and psychogenic origins, or mixed causes. It is not intended for use by women, children, or men without erectile dysfunction.

Dosage and direction

The recommended starting dose for most patients is 50 mg taken approximately one hour prior to anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. Dosing should be limited to a maximum of once per 24-hour period. The softgel should be swallowed whole with a glass of water; it may be taken with or without food, though a high-fat meal may delay the time to onset of effect.

Precautions

• A thorough medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes before prescribing.
• Physicians should consider the cardiovascular status of their patients, as sexual activity carries a potential cardiac risk. Sildigra Softgel is not recommended for use in men for whom sexual activity is inadvisable.
• Patients should be advised to avoid excessive alcohol consumption (e.g., 5 units or more) prior to sexual activity, as it can impair the ability to get an erection and increase the incidence of adverse effects such as dizziness and orthostatic hypotension.
• Use with caution in patients with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie’s disease) or conditions that may predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia).

Contraindications

• Concomitant administration with any form of organic nitrates (e.g., nitroglycerin, isosorbide mononitrate or dinitrate) or nitric oxide donors in any form. This combination can lead to a profound and potentially life-threatening drop in blood pressure.
• Hypersensitivity to sildenafil citrate or any of the excipients listed in the softgel formulation.
• Concurrent use with guanylate cyclase stimulators, such as riociguat.
• Men for whom sexual activity is not recommended due to underlying cardiovascular status.

Possible side effect

The following adverse reactions are associated with PDE5 inhibition and are typically transient and mild to moderate in nature.

• Very Common (≥1/10): Headache, flushing.
• Common (≥1/100 to <1/10): Dyspepsia, nasal congestion, dizziness, visual disturbances (including blurred vision, cyanopsia), back pain, myalgia.
• Uncommon (≥1/1,000 to <1/100): Hypotension, syncope, tachycardia, palpitations, hematuria, eye pain, photophobia, conjunctival hyperemia, tinnitus, vertigo.
• Rare but serious: Priapism (a prolonged and painful erection lasting more than 4 hours), sudden hearing loss, non-arteritic anterior ischemic optic neuropathy (NAION).

Drug interaction

• Nitrates: Concomitant use is absolutely contraindicated due to the risk of severe hypotension.
• Alpha-adrenergic blockers: (e.g., doxazosin, tamsulosin). Concomitant use can potentiate the blood-pressure-lowering effects. A separation of dosing times may be required, and the lowest dose of sildigra should be considered.
• Potent CYP3A4 inhibitors: (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin). These drugs can significantly increase sildenafil plasma concentrations. A maximum dose of 25 mg within a 48-hour period is recommended.
• Antihypertensives: Additive hypotensive effects may occur when used with other antihypertensive medications.
• Alcohol: Potentiates the hypotensive and vasodilatory effects.

Missed dose

Sildigra Softgel is not intended for chronic daily dosing and is taken on an as-needed basis. Therefore, the concept of a “missed dose” does not apply. Do not take an extra dose to make up for a missed opportunity.

Overdose

In cases of overdose, the expected clinical findings would be an extension of the drug’s known adverse effects, including severe hypotension, syncope, and prolonged erection. Standard supportive measures should be employed as required. Given sildenafil’s high protein binding, dialysis is not expected to accelerate clearance. Management of priapism requires immediate medical intervention to avoid long-term penile tissue damage and impotence.

Storage

Store at room temperature (15°-30°C or 59°-86°F) in the original container. Protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.

Reviews

• “As a urologist with over 20 years of experience, the softgel formulation of sildenafil offers a tangible benefit in terms of patient-reported onset time. Many of my patients prefer it over the traditional tablet.” – Dr. A. Reynolds, MD.
• “Noticed a significant difference in consistency of effect. The softgel seems to work more reliably for me, even if I’ve had a light meal. A worthwhile option to discuss with your doctor.” – Verified Patient, 54.
• “The pharmacological profile is well-established, but the delivery system in Sildigra Softgel appears to enhance bioavailability. This is a logical and welcome evolution of a first-line ED therapy.” – Clinical Pharmacologist Review.